

Here are today's emails from the lancet

**From:** D [REDACTED] <d[REDACTED]@lancet.com>

**Date:** November 26, 2012, 8:22:57 AM CST

**To:** <[REDACTED]@burzynskiclinic.com>

**Subject:** Your Submission to The Lancet Oncology

Manuscript reference number: THELANCETONCOLOGY-D-12-01519

Title: Glioblastoma multiforme: a report of long-term progression-free survival and overall survival of 8 to over 16 years after antineoplaston therapy and review of literature

Dear Dr. Burzynski,

Thank you for your recent submission to The Lancet Oncology. We have now had time to consider your manuscript and unfortunately, on this occasion, we have decided not to publish it because we believe the message would be better elsewhere.

Although this decision has not been a positive one, I thank you for your interest in the journal and hope it does not deter you from considering us again in the future.

Yours sincerely,

Dr. D [REDACTED]  
Editor, The Lancet Oncology  
32 Jamestown Road  
London NW17BY  
UNITED KINGDOM  
Tel: +44 [REDACTED]  
Fax: +4 [REDACTED]  
Email: d[REDACTED]@lancet.com

**From:** The Lancet Oncology Peer Review Team

<[REDACTED]TheLancetOncology@[REDACTED].com>

**Date:** November 26, 2012, 6:13:08 AM CST

**To:** <[REDACTED]@burzynskiclinic.com>

**Subject:** Manuscript Reference Number For Your Submission to The Lancet Oncology

Dear Dr. Burzynski,

Your submission, Glioblastoma multiforme: a report of long-term progression-free survival and overall survival of 8 to over 16 years after antineoplaston therapy and review of literature, has been assigned to an editor and now has the following manuscript reference number: THELANCETONCOLOGY-D-12-01519.

Please quote this number in any correspondence you have with us as it will enable us to efficiently handle any queries you may have.

As your manuscript passes through the selection process you will be able to view its progress by visiting the The Lancet Oncology's Online Submission and Peer Review website (EES) at <http://ees.elsevier.com/thelancetoncology/>.

**IMPORTANT:** If you have not uploaded your statements of Author contribution with your submission, please do not do so until requested.

Please note that if your article is unsuccessful at The Lancet Oncology, for selected papers, we might recommend, in the decision letter, other cancer journals published by Elsevier as a possible home for your manuscript. You will be under no obligation to accept this recommendation, it is simply offered in an advisory capacity. If such a recommendation is not explicitly made, then we are unable to offer any advice on alternative journals for the manuscript.

Thank you for submitting your work to us.

Yours sincerely,

The Lancet

Two hours later, this Phase 2 report was rejected.